TMCI Stock Forecast & Price Target

Treace Medical Concepts Inc. has demonstrated a 7.0% year-over-year increase in active surgeon users, which reflects growing adoption of its Lapiplasty system despite a slight decline in utilization per surgeon. The company’s strategic initiatives, including enhanced direct-to-consumer programs, physician education, and an expanded sales force, are anticipated to positively impact revenue growth, particularly in fiscal year 2026, as it aims to capture a larger share of both the bunion and complementary foot and ankle markets. Additionally, there is potential for improved profit margins driven by higher average selling prices for products and increased sales of ancillary items, which together position the company favorably in a competitive landscape.

Treace Medical Concepts Inc. is forecasting a significant decline in revenue for the fourth quarter, with projections of approximately $61.8 million, reflecting a year-over-year decrease of about 10%. The company's revenue guidance for fiscal year 2025 has also been revised downward, from $224-230 million to a range of $211-213 million due to a slowdown in elective procedures and adverse market conditions affecting the adoption of their Lapiplasty procedure. Furthermore, anticipated negative year-over-year revenue growth in 2026, exacerbated by reduced customer demand for bunion corrective procedures, suggests a challenging outlook for the company's financial performance in the near term.